Publication:
What's new in the treatment of urticaria and angioedema

dc.contributor.coauthorKhan, David A.
dc.contributor.coauthorBauer, Andrea
dc.contributor.coauthorAygoeren-Pursuen, Emel
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKocatürk Göncü, Özgür Emek
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:09:39Z
dc.date.issued2021
dc.description.abstractChronic urticaria and angioedema are diseases often managed by Allergy and Immunology specialists. Recent international guidelines have outlined a stepwise approach to management of patients using dose escalation of second-generation antihistamines followed by use of omalizumab and finally cyclosporine in more refractory cases. In select patients (those with refractory chronic urticaria), nonbiologic alternative medications with anti-inflammatory or immunosuppressant activity may be considered. Angioedema without wheals may have several different pathophysiologic mechanisms. Optimal management of mast cell-mediated angioedema is less clear but is often managed similar to chronic spontaneous urticaria. Drug-induced angioedema due to angiotensin-converting enzyme inhibitors is a common cause of angioedema in the emergency department. Although bradykinin is thought to be a primary mediator for this type of angioedema, studies of targeted therapies have been generally disappointing. In contrast, several targeted therapies have been proven successful using acute and preventive approaches for management of hereditary angioedema. Further developments, including novel biologics, novel oral therapies, and gene therapy approaches, may hopefully continue to broaden therapeutic options to ensure optimal individual management of patients with hereditary angioedema.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue6
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume9
dc.identifier.doi10.1016/j.jaip.2021.03.012
dc.identifier.eissn2213-2201
dc.identifier.issn2213-2198
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85106867728
dc.identifier.urihttps://doi.org/10.1016/j.jaip.2021.03.012
dc.identifier.urihttps://hdl.handle.net/20.500.14288/9343
dc.identifier.wos675846800006
dc.keywordsChronic urticaria
dc.keywordsAngioedema
dc.keywordsAlternative therapies
dc.keywordsMast cellemediated angioedema
dc.keywordsACE-I angioedema
dc.keywordsHereditary angioedema
dc.keywordsManagement
dc.keywordsRefractory chronic urticaria
dc.keywordsInhibitor-induced angioedema
dc.keywordsBand ultraviolet-B
dc.keywordsQuality-of-life
dc.keywordsHereditary angioedema
dc.keywordsSubcutaneous C1-inhibitor
dc.keywordsTherapeutic alternatives
dc.keywordsOmalizumab treatment
dc.keywordsHumanistic burden
dc.keywordsPlasma kallikrein
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofJournal of Allergy and Clinical Immunology-in Practice
dc.subjectAllergy
dc.subjectImmunology
dc.titleWhat's new in the treatment of urticaria and angioedema
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorKocatürk Göncü, Özgür Emek
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files